Zenas BioPharma, Inc. Common Stock (ZBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.90B
Last updated: Nov 17, 2026 at 11:06 AM ET
Zenas BioPharma, Inc. Common Stock (ZBIO) Financials: Revenue, Profit and Cash Flow
Zenas BioPharma, Inc. Common Stock reported revenue of $10.00M for the fiscal year ended Dec 31, 2025, up 100.0% from the year before. That year, net income was -$377.74M with a net margin of -3777.4%, operating cash flow was -$172.33M and free cash flow was -$172.35M. The quarter ended Sep 30, 2026 had revenue of $10.00M and net income of -$108.92M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $10.00M | +100.0% | 100.0% | -3830.6% | -3777.4% |
| Dec 2024 | $5.00M | -90.0% | 100.0% | -3277.8% | -3139.8% |
| Dec 2023 | $50.00M | N/A | 100.0% | -74.3% | -74.2% |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | $10.00M | $5.00M | $50.00M | $0 |
| Cost of revenue | $0 | $0 | $0 | $61.69M |
| Gross profit | $10.00M | $5.00M | $50.00M | -$61.69M |
| Research and development | $339.74M | $139.14M | $70.03M | $62.69M |
| Operating income | -$383.06M | -$163.89M | -$37.15M | -$76.20M |
| Net income | -$377.74M | -$156.99M | -$37.12M | -$119.28M |
| EBITDA | N/A | N/A | -$36.71M | -$75.12M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.00M | $1.00M | $0 | $10.00M | $0 | $0 | $10.00M | $5.00M | $0 | $0 | $0 | $0 |
| Gross profit | $10.00M | $1.00M | $0 | -$10.00K | $0 | $0 | $10.00M | $5.00M | $0 | $0 | $0 | -$20.42M |
| Operating income | -$103.41M | -$107.66M | -$77.35M | -$237.98M | -$52.58M | -$55.16M | -$37.33M | -$55.62M | -$40.98M | -$39.70M | -$27.58M | -$24.78M |
| Net income | -$108.92M | -$111.46M | -$80.99M | -$240.44M | -$51.50M | -$52.22M | -$33.57M | -$52.60M | -$38.61M | -$37.98M | -$27.80M | -$24.59M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $1.11M by $109.53M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total assets | $383.64M | $369.97M | $68.18M | $74.58M |
| Current assets | $351.17M | $355.92M | $59.80M | $68.44M |
| Cash and equivalents | $110.64M | $319.74M | $56.86M | $67.21M |
| Total liabilities | $141.50M | $57.51M | $43.81M | $266.87M |
| Short-term debt | $1.11M | $785.00K | $556.00K | $715.00K |
| Long-term debt | $0 | $0 | $20.30M | N/A |
| Shareholder equity | $242.14M | $312.46M | -$225.72M | -$192.29M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $675.22M | $701.69M | $747.68M | $383.64M | $322.02M | $293.08M | $333.77M | $369.97M | $403.43M | $199.95M | $49.05M | $68.18M |
| Total liabilities | $462.91M | $454.59M | $411.85M | $141.50M | $125.59M | $53.46M | $49.45M | $57.51M | $44.00M | $39.12M | $301.55M | $293.90M |
| Cash and equivalents | $177.78M | $196.58M | $500.22M | $110.64M | $115.56M | $44.01M | $196.55M | $319.74M | $360.04M | $183.93M | $37.15M | $56.86M |
| Shareholder equity | $212.31M | $247.10M | $335.83M | $242.14M | $196.43M | $239.63M | $284.32M | $312.46M | $359.44M | $160.83M | -$252.50M | -$225.72M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating cash flow | -$172.33M | -$119.67M | -$30.53M | -$65.65M |
| Capital expenditures | $18.00K | $131.00K | $17.00K | $2.20M |
| Free cash flow | -$172.35M | -$119.81M | -$30.55M | -$67.85M |
| Share repurchases | $12.66M | $6.33M | $0 | N/A |
| Investing cash flow | -$251.89M | -$30.55M | -$17.00K | -$2.20M |
| Financing cash flow | $215.28M | $412.96M | $20.12M | $59.39M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$57.98M | -$57.24M | -$75.20M | -$52.41M | -$41.13M | -$41.74M | -$37.05M | -$38.55M | -$31.06M | -$30.96M | -$19.10M | -$15.40M |
| Capital expenditures | $1.00K | N/A | $2.00K | $30.00M | $5.00M | $0 | $18.00K | $74.00K | $0 | $35.00K | $22.00K | $17.00K |
| Free cash flow | -$57.98M | N/A | -$75.20M | -$82.41M | -$46.13M | -$41.74M | -$37.07M | -$38.63M | -$31.06M | -$30.99M | -$19.12M | -$15.42M |
Frequently Asked Questions About ZBIO
What is Zenas BioPharma, Inc. Common Stock's annual revenue?
Zenas BioPharma, Inc. Common Stock reported revenue of $10.00M for the fiscal year ended Dec 31, 2025.
How fast is Zenas BioPharma, Inc. Common Stock's revenue growing?
Revenue was up 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Zenas BioPharma, Inc. Common Stock profitable?
No. Zenas BioPharma, Inc. Common Stock reported net income of -$377.74M for the fiscal year ended Dec 31, 2025, with a net margin of -3777.4%.
How much free cash flow does ZBIO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$172.33M minus capital expenditures of $18.00K produced free cash flow of -$172.35M.
How much debt does Zenas BioPharma, Inc. Common Stock have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $1.11M and cash and equivalents of $110.64M.
ZBIO pages: Overview, Earnings, Forecast, Financials, Competitors